Fig. 4

The superior anti-tumor activity of CD5 CAR-NK cells in vivo. (a) Schematic representation of the in vivo experimental timeline. (b) Tumor growth and staging monitored by BLI. (c) Average radiance quantification for each group at the indicated time points. The results are presented as mean ± SD (n = 5). (d) Kaplan–Meier survival curve for each group. Data are presented as mean ± SD (n = 5). (e) Body weight curve for each group. The results are presented as mean ± SD (n = 5). (f) Percentage of CAR-NK, CAR-T, and NK cells in the peripheral blood of the mice (n = 5). (g) Representative images of immunofluorescence labeling of infiltrating tumor cells (CD5, green), NK/CAR-NK cells (CD56, red), or CAR-T cells (CD3, pink) in the spleen (left) and liver (right) of mice treated with CAR-NK, NK, CAR-T cells, or control